Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus-Reference-Cited by-同舟云学术

Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus

Published:2016-07 Issue:29 Volume:95 Page:e4283
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Inadomi Kyoko,Kumagai Hozumi,Arita Shuji,Tsuruta Nobuhiro,Takayoshi Kotoe,Mishima Koji,Ota Shun-Ichiro,Tanaka Mamoru,Okumura Yuta,Sagara Kosuke,Nio Kenta,Nakano Michitaka,Uchi Hiroshi,Yamamoto Hidetaka,Ariyama Hiroshi,Kusaba Hitoshi,Niiro Hiroaki,Oda Yoshinao,Akashi Koichi,Baba Eishi

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference12 articles.

1. Primary malignant melanoma of the esophagus associated with adenocarcinoma of the lung;Yano;Surg Today,1998

2. Current systemic therapy for metastatic melanoma;Agarwala;Expert Rev Anticancer Ther,2009

3. Nivolumab in Previously Untreated Melanoma without BRAF Mutation;Robert;N Engl J Med,2015

4. PD-1 as a potential target in cancer therapy;McDermott;Cancer Med,2013

5. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab;International Cancer Conference Journal;2022-12-21

2. The Thousand Faces of Malignant Melanoma: A Systematic Review of the Primary Malignant Melanoma of the Esophagus;Cancers;2022-07-30

3. Hematology;Managing Immunotherapy Related Organ Toxicities;2022

4. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update;Journal of Clinical Oncology;2021-12-20

5. Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation;Hematology;2021-12-10